Cargando…

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer

The changes in serum prostate-specific antigen (PSA) concentrations can be used as a prognostic factor in patients undergoing maximum androgen blockage for metastatic prostate cancer. A total of 149 patients followed in our department were classified into 4 groups on the basis of PSA changes: group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiper, Ahmet, Yiğitbasi, Orhan, Imamoglu, Abdurrahim, Tuygun, Can, Turan, Celaleddin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936603/ https://www.ncbi.nlm.nih.gov/pubmed/15702224 http://dx.doi.org/10.1100/tsw.2005.19

Ejemplares similares

Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients
por: Ersoy, Hamit, et al.
Publicado: (2008)

The Unusual Mass of Retrovesical Space: A Secondary Hydatid Cyst D?sease
por: Tuygun, Can, et al.
Publicado: (2006)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer
por: Krönig, Malte, et al.
Publicado: (2017)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
por: Murray, Nigel P., et al.
Publicado: (2011)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

Retrograde Intrarenal Surgery versus Percutaneous Lithotripsy to Treat Renal Stones 2-3 cm in Diameter
por: Zengin, Kursad, et al.
Publicado: (2015)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer
por: Cherrier, M. M., et al.
Publicado: (2018)

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
por: Choi, Joon Il, et al.
Publicado: (2011)

Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer
por: Kondo, Takeshi, et al.
Publicado: (2016)

Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells
por: Sommer, Ulrich, et al.
Publicado: (2022)

A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
por: Christie, David R.H., et al.
Publicado: (2021)

A Rare Case of Prostate-Specific Antigen–Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance
por: Andrews, Jack R., et al.
Publicado: (2020)

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis
por: Afriansyah, Andika, et al.
Publicado: (2018)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Androgens and prostate disease
por: Cooper, Lori A, et al.
Publicado: (2014)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
por: Theyer, G., et al.
Publicado: (1997)

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2004)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma
por: Kidwai, Noman, et al.
Publicado: (2004)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
por: Raju, Govinda Nanjaiah Laxmana, et al.
Publicado: (2022)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells
por: Ramos-Torres, Ágata, et al.
Publicado: (2015)

HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression
por: Kim, Sin Do, et al.
Publicado: (2010)

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma
por: Chen, Yehui, et al.
Publicado: (2017)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

THU544 Prostatic Acid Phosphatase Is Negatively Regulated By Androgens And Persists In Castrate-resistant Metastatic Prostate Cancer
por: Rajagopalan, Vinodh, et al.
Publicado: (2023)

Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer
por: Takakusagi, Yosuke, et al.
Publicado: (2020)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy
por: Lim, Jasmine, et al.
Publicado: (2020)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pm7ja5nnfmr17do8fcd4hg6t1t